Displaying all 13 publications

Abstract:
Sort:
  1. Xanthomycin A
    Dougall D, Abraham EP
    Nature, 1955;176:256.
    DOI: 10.1038/176256a0
    WHILE studying the antibacterial products of a species of Streptomyces (N.C.I.B. 8697) sent by Dr. R. Green from Malaya, we have isolated an orange-red coloured basic substance which is very active against a variety of bacteria and is highly toxic to mice. The antibiotic was extracted from the culture fluid into chloroform, at pH 6, and re-extracted into water at pH 2, or extracted into trichloroethylene, at pH 8.5, and re-extracted into water at pH 3.5. It was purified by counter-current distribution in a solvent system consisting of trichloroethylene and 0.1 M sodium citrate buffer, pH. 5.95. In this system its partition coefficient, K (Combining double low line concentration in trichloroethylene/concentration in water), was 0.98. The purified product yielded a crystalline hydrochloride, reineckate and picrate. The behaviour of this antibiotic suggests that it is identical with, or very closely related to, xanthomycin A - a substance which has been isolated from species of Streptomyces1, and stated to have quinonoid properties2. We wish to record, however, that it is a stronger base than xanthomycin A has been reported to be and that it yields two simple bases on hydrolysis which have not been described as degradation products of xanthomycin A. © 1955 Nature Publishing Group.
    Matched MeSH terms: Antibiotics, Antitubercular
  2. Epidemic kerato-conjunctivitis in Malaya
    SINGH K
    Med J Malaya, 1962 Sep;17:4-11.
    PMID: 13977655
    Matched MeSH terms: Antibiotics, Antitubercular*
  3. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers
    Chik Z, Basu RC, Pendek R, Lee TC, Mohamed Z
    Clin Ther, 2010 Sep;32(10):1822-31.
    PMID: 21194606 DOI: 10.1016/j.clinthera.2010.09.006
    Rifampicin is a semisynthetic antibiotic derivative of rifamycin used worldwide for the treatment of various forms of tuberculosis.
    Matched MeSH terms: Antibiotics, Antitubercular/administration & dosage*; Antibiotics, Antitubercular/blood; Antibiotics, Antitubercular/pharmacokinetics*
  4. Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?
    Lee SL, Lim WJ, Chai ST
    Med J Malaysia, 2020 09;75(5):591-593.
    PMID: 32918434
    A 67-year-old mental institute resident was treated for smear-positive pulmonary tuberculosis. His background history included chronic essential hypertension which was well-controlled with amlodipine 10mg daily. However, his blood pressure became suboptimal one week into antitubercular treatment, necessitating escalation of antihypertensive therapy up to six medications. Following completion of antitubercular treatment, his blood pressure improved markedly. The number of antihypertensives was able to be reduced to only two after a month. We postulate that rifampicin has attenuated the therapeutic effect of amlodipine via potent induction of hepatic CYP3A4 but the failure to control the blood pressure even with medications unrelated to cytochrome P450 pathways raises the spectre of an additional interaction.
    Matched MeSH terms: Antibiotics, Antitubercular/adverse effects*; Antibiotics, Antitubercular/pharmacology*
  5. Abnormal dexamethasone suppression tests in a rifampicin-treated patient with suspected Cushing's syndrome
    Abdullah HN, Nowalid WK
    Endokrynol Pol, 2010 Nov-Dec;61(6):706-9.
    PMID: 21104646
    The dexamethasone suppression test is a useful endocrinological test to diagnose Cushing's syndrome. However, its interpretation may be influenced by many factors such as stress, alcohol, failure to ingest the dexamethasone, altered metabolism, drug interaction and obesity. This report illustrates such an instance, whereby the result of the test was erratic due to the anti-tuberculous drug rifampicin. Rifampicin has been found to profoundly attenuate the biological effects of dexamethasone, probably by enhancing its metabolism in the liver. The exact mechanism of the drug interaction remains elusive, though induction of hepatic CYP3A4 enzyme complex is a possible mechanism. In a patient treated with rifampicin, the results of dexamethasone suppression tests thus have no diagnostic value and can be very misleading.
    Matched MeSH terms: Antibiotics, Antitubercular/pharmacology*
  6. Fulltext An evidence-based clinical pathway for the diagnosis of tuberculous lymphadenitis: A systematic review
    Sivaratnam L, Nawi AM, Abdul Manaf MR
    Int J Mycobacteriol, 2020 6 1;9(2):107-115.
    PMID: 32474531 DOI: 10.4103/ijmy.ijmy_207_19
    To achieve the World Health Organization end TB Strategy, early detection, and prompt treatment of not only pulmonary but also extrapulmonary tuberculosis (EPTB) should be achieved. The most common EPTB is tuberculous lymphadenitis, and the diagnosis is typically time-consuming. This review aimed to identify the best diagnostic pathway for preventing treatment delay and thus further complications. A systematic keyword search was done using four databases and other relevant publications and using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart to search for relevant articles that met the inclusion criteria. The quality of the articles was assessed using Newcastle-Ottawa Scale, and the articles were summarized based on the test for diagnosing tuberculous lymphadenitis. A total of ten articles were included for the synthesis of results, which compared the sensitivity and specificity of each diagnostic test for tuberculous lymphadenitis. The most promising test is the Xpert Mycobacterium tuberculosis/RIF, which has high sensitivity and specificity, but costs much more in comparison to the other tests. An ideal diagnostic method should include the combination of relevant patient history, clinical examination, and laboratory and radiological testing to avoid delays in treatment, misdiagnosis, and further complications.
    Matched MeSH terms: Antibiotics, Antitubercular/therapeutic use
  7. Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation
    Parumasivam T, Ashhurst AS, Nagalingam G, Britton WJ, Chan HK
    Mol Pharm, 2017 01 03;14(1):328-335.
    PMID: 27977216 DOI: 10.1021/acs.molpharmaceut.6b00905
    Rifapentine is an anti-tuberculosis (anti-TB) drug with a prolonged half-life, but oral delivery results in low concentrations in the lungs because of its high binding (98%) to plasma proteins. We have shown that inhalation of crystalline rifapentine overcomes the limitations of oral delivery by significantly enhancing and prolonging the drug concentration in the lungs. The delivery of crystalline particles to the lungs may promote inflammation. This in vivo study characterizes the inflammatory response caused by pulmonary deposition of the rifapentine particles. The rifapentine powder was delivered to BALB/c mice by intratracheal insufflation at a dose of 20 mg/kg. The inflammatory response in the lungs and bronchoalveolar lavage (BAL) was examined at 12 h, 24 h, and 7 days post-treatment by flow cytometry and histopathology. At 12 and 24 h post-treatment, there was a significant influx of neutrophils into the lungs, and this returned to normal by day 7. A significant recruitment of macrophages occurred in the BAL at 24 h. Consistent with these findings, histopathological analysis demonstrated pulmonary vascular congestion and significant macrophage recruitment at 12 and 24 h post-treatment. In conclusion, the pulmonary delivery of crystalline rifapentine caused a transient neutrophil-associated inflammatory response in the lungs that resolved over 7 days. This observation may limit pulmonary delivery of rifapentine to once a week at a dose of 20 mg/kg or less. The effectiveness of weekly dosing with inhalable rifapentine will be assessed in murine Mycobacterium tuberculosis infection.
    Matched MeSH terms: Antibiotics, Antitubercular/administration & dosage; Antibiotics, Antitubercular/adverse effects
  8. An apparently healthy young man with a peculiar-looking chest radiograph
    Khajotia R, Manthari K
    Can Fam Physician, 2011 Mar;57(3):311-3.
    PMID: 21402968
    Matched MeSH terms: Antibiotics, Antitubercular/therapeutic use
  9. Fulltext Influences of proton pump inhibitor on Helicobacter pylori adherence to the gastrointestinal cell lines
    Omar MS, Damanhuri NS, Kumolosasi E
    Turk J Gastroenterol, 2017 Jan;28(1):53-59.
    PMID: 27991853 DOI: 10.5152/tjg.2016.0409
    BACKGROUND/AIMS: Helicobacter pylori is a carcinogenic bacterium that could induce P-glycoprotein expression in the human gastrointestinal tract. Bacterial adherence to the gastrointestinal cell lines could be influenced by the level of P-glycoprotein. This study aimed to determine the influence of proton pump inhibitors that exhibit an inhibitory effect on P-glycoprotein in gastrointestinal carcinoma cell lines, namely Caco-2 and LS174T, in relation to H. pylori adherence.

    MATERIALS AND METHODS: Caco-2 and LS174T cells lines treated with omeprazole and esomeprazole were used in this study to assess the bacterial attachment of H. pylori within certain incubation periods.

    RESULTS: The presence of proton pump inhibitors increased the H. pylori adherence in a time-dependent manner in both Caco-2 and LS174T cell lines. The double inhibition of P-glycoprotein using proton pump inhibitor and P-glycoprotein inhibitor caused low P-glycoprotein expression in the cell lines, resulting in higher H. pylori adherence compared to the control cell lines.

    CONCLUSION: Proton pump inhibitors may alter P-glycoprotein expression in the gastrointestinal tract, and subsequently H. pylori adherence on the cell lines, and may contribute to resistance to drug therapy.

    Matched MeSH terms: Antibiotics, Antitubercular/pharmacology
  10. Fulltext Lady Windermere syndrome: an inappropriate eponym for an increasingly important condition
    Kasthoori JJ, Liam CK, Wastie ML
    Singapore Med J, 2008 Feb;49(2):e47-9.
    PMID: 18301826
    Non-tuberculous mycobacterial infection (NMI) occurs in elderly women with no pre-existing lung disease, and this has been termed the Lady Windermere syndrome. NMIs are increasing in prevalence and an increasing number of pulmonary mycobacterial infections is due to non-tuberculous mycobacteria. The diagnosis is often difficult because the organism is not readily isolated or cultured, and the condition may not be considered by the radiologist. We report NMI in a 64-year-old woman, based on clinical and radiological findings. Although termed the Lady Windermere syndrome, the name does not correspond to the character in Oscar Wilde's play; hence the eponym is not widely used.
    Matched MeSH terms: Antibiotics, Antitubercular/therapeutic use
  11. Mucoadhesive guargum hydrogel inter-connected chitosan-g-polycaprolactone micelles for rifampicin delivery
    Yuan X, Amarnath Praphakar R, Munusamy MA, Alarfaj AA, Suresh Kumar S, Rajan M
    Carbohydr Polym, 2019 Feb 15;206:1-10.
    PMID: 30553301 DOI: 10.1016/j.carbpol.2018.10.098
    Natural polymer guar gum has one of the highest viscosities in water solution and hence, these are significantly used in pharmaceutical applications. Guar gum inter-connected micelles as a new carrier has been developed for poor water soluble rifampicin drug. The hydrogel inter-connected micelle core was formulated as a hydrophilic inner and hydrophobic outer core by using guar gum/chitosan/polycaprolactone and the carrier interaction with rifampicin was confirmed by FT-IR. The morphological observations were carried out through TEM, SEM and AFM analysis. The encapsulation efficiency and in-vitro drug release behavior of prepared hydrogel based micelle system was analyzed by UV-vis spectrometry. The anti-bacterial activity against K. pneumoniae and S. aureus was studied by observing their ruptured surface by SEM. The cytotoxicity study reveals that the pure polymeric system has no toxic effect whereas drug loaded ones showed superior activity against THP-1 cells. From the cell apoptosis analyses, the apoptosis was carried out in a time dependent manner. The cell uptake behavior was also observed in THP-1 cells which indicate that the hydrogel based micelle system is an excellent material for the mucoadhesive on intracellular alveolar macrophage treatment.
    Matched MeSH terms: Antibiotics, Antitubercular/pharmacology*; Antibiotics, Antitubercular/chemistry
  12. The reliability of a rapid molecular detection method in determining the prevalence of rifampicin-resistant Mycobacterium tuberculosis in an urban district health facility in Malaysia
    Ding CH, Ismail Z, Sulong A, Wahab AA, Gan B, Mustakim S, et al.
    Malays J Pathol, 2020 Dec;42(3):401-407.
    PMID: 33361721
    INTRODUCTION: Rifampicin is a key first-line antimycobacterial agent employed for the treatment of pulmonary tuberculosis (PTB). This study sought to obtain prevalence data on rifampicin-resistant Mycobacterium tuberculosis among smear-positive PTB patients in the Klang District of Malaysia.

    MATERIALS AND METHODS: A total of 103 patients from the Chest Clinic of Hospital Tengku Ampuan Rahimah with sputum smears positive for acid-fast bacilli were included in this cross-sectional study. All sputa were tested using Xpert MTB/RIF to confirm the presence of M. tuberculosis complex and detect rifampicin resistance. Sputa were also sent to a respiratory medicine institute for mycobacterial culture. Positive cultures were then submitted to a reference laboratory, where isolates identified as M. tuberculosis complex underwent drug susceptibility testing (DST).

    RESULTS: A total of 58 (56.3%) patients were newly diagnosed and 45 (43.7%) patients were previously treated. Xpert MTB/RIF was able to detect rifampicin resistance with a sensitivity and specificity of 87.5% and 98.9%, respectively. Assuming that a single resistant result from Xpert MTB/RIF or any DST method was sufficient to denote resistance, a total of 8/103 patients had rifampicinresistant M. tuberculosis. All eight patients were previously treated for PTB (p<0.05). The overall prevalence of rifampicin resistance among smear-positive PTB patients was 7.8%, although it was 17.8% among the previously treated ones.

    CONCLUSION: The local prevalence of rifampicin-resistant M. tuberculosis was particularly high among previously treated patients. Xpert MTB/RIF can be employed in urban district health facilities not only to diagnose PTB in smear-positive patients, but also to detect rifampicin resistance with good sensitivity and specificity.

    Matched MeSH terms: Antibiotics, Antitubercular/therapeutic use
  13. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management
    Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, et al.
    J Gastroenterol Hepatol, 2018 Jan;33(1):30-36.
    PMID: 29024102 DOI: 10.1111/jgh.14018
    Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in this region. Thus, the Asian Organization for Crohn's and Colitis and the Asia Pacific Association of Gastroenterology have developed a set of consensus statements about risk assessment, detection and prevention of latent TB infection, and management of active TB infection in patients with inflammatory bowel disease (IBD) receiving anti-TNF treatment. Twenty-three consensus statements were initially drafted and then discussed by the committee members. The quality of evidence and the strength of recommendations were assessed by using the Grading of Recommendations Assessment, Development, and Evaluation methodology. Web-based consensus voting was performed by 211 IBD specialists from nine Asian countries concerning each statement. A consensus statement was accepted if at least 75% of the participants agreed. Part 2 of the statements comprised three parts: (3) management of latent TB in preparation for anti-TNF therapy, (4) monitoring during anti-TNF therapy, and (5) management of an active TB infection after anti-TNF therapy. These consensus statements will help clinicians optimize patient outcomes by reducing the morbidity and mortality related to TB infections in patients with IBD receiving anti-TNF treatment.
    Matched MeSH terms: Antibiotics, Antitubercular/administration & dosage*
Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links